Data Bytes: Trodelvy leads TROP2 pack

Five therapies in the TROP2 pipeline together address at least seven types of cancer plus undisclosed solid tumors.

The most advanced, Trodelvy sacituzumab govitecan-hziy, is the centerpiece of the $21 billion acquisition of  Immunomedics Inc. by Gilead Sciences Inc. (NASDAQ:GILD). The $88-per-share price represented a 108% premium and is the largest biotech takeover so far in 2020, and the largest ever for Gilead (see “Takeout Premium in $21B Deal Shows Gilead’s Confidence”). ...